The use of the ketogenic diet in the treatment of epileptic encephalopathies

Roberto H Caraballo MD
Department of Neurology, Hospital de Pediatria "Prof Dr Juan P Garrahan", Buenos Aires, Argentina

Corresponding author: Roberto Caraballo, Department of Neurology, Hospital de Pediatria Juan P. Garrahan, Combate de los Pozos 1881, Buenos Aires, Argentina CP 1245, Telephone Number: +54 11 4824 0299. Fax Number: +54 11 4843 6116.e-mail: rhcaraballo@arnet.com.ar

ABSTRACT

Epileptic encephalopathies (EE) are severe conditions characterized by paroxysmal activity on the electroencephalogram (EEG) that is often aggressive, associated with severe cognitive and behavioural disturbances that present or worsen after the onset of epilepsy. The ketogenic diet (KD) has been shown to be effective in the treatment of refractory EE, and has been suggested for early treatment in very young children.

Although the experience is often anecdotal and mostly consists of case reports and case series, the aim of this study was to present our own experience with an overview of the current literature on the diet in patients with EE.

Some encephalopathies, such as epilepsy with myoclonic and atonic seizures (EMAS), West syndrome (WS), Dravet syndrome (DS), or Lennox-Gastaut syndrome (LGS), are well recognized and known to have a good response to the KD. Others are more rare or have only recently been identified, so the KD has only been tried in sporadic cases (i.e. epilepsy with focal migrating seizures in infancy, febrile infection-related epilepsy syndrome, or myclonic status in non-progressive encephalopathy). The KD should be considered earlier in the therapeutic scheme of these severe epileptic syndromes. The KD, including the oral formula, may be considered in all paediatric patients with EE even in infancy.

Keywords: Epileptic encephalopathies, ketogenic diet, children, refractory, outcome.

INTRODUCTION

Epileptic encephalopathies (EE) are severe conditions characterized by paroxysmal activity on the electroencephalogram (EEG) that is often aggressive, manifesting as seizures that are commonly multi-form and intractable, and associated with severe cognitive and behavioural disturbances. These syndromes differ regarding age at onset, developmental outcomes, aetiologies, neuropsychological deficits, EEG patterns, seizure types, and prognosis [1], but have in common that the cause of the progressive cognitive and neuropsychological deterioration is considered to be related to the seizures and severe epileptiform EEG abnormalities during brain maturation [2, 3].

Recently, Howell et al. [4] proposed to restrict the term EE to the central concept of a pervasive epileptic process disrupting development rather than to consider them as epileptic syndromes. Based on these definitions, in this review we considered the following list of EE according to age at onset (see also Table 1):

- Early myoclonic encephalopathy (EME)
- Early infantile epileptic encephalopathy, or Ohtahara syndrome (OS)
- Infantile spasms (IS), or West syndrome (WS)
- Epileptic spasms in clusters without hypsarrhythmia
- Severe myoclonic epilepsy in infancy (SMEI), or Dravet syndrome (DS)
- Migrating partial seizures in infancy (MFSI)
- Epilepsy with myoclonic and atonic seizures (EMAS), or Doose syndrome
- Myoclonic status epilepticus in nonprogressive encephalopathies (MSENPE), or Dalla Bernardina syndrome
- Lennox-Gastaut syndrome (LGS)
- Landau-Kleffner syndrome (LKS) or Acquired epileptic aphasia
- Epilepsy with continuous spike-waves during slow-wave sleep (CSWS)
- Febrile infection-related epilepsy syndrome (FIRES)

The factors that play a role in the development towards EE are often not identified [2]. The aetiologies may be genetic, structural/metabolic, or unknown. Considering that the cognitive and behavioural disturbances are caused by the epileptic and epileptiform activity, suppressing this activity may lead to improvement of the neuropsychological outcome. Nevertheless, EE are usually refractory to standard antiepileptic drugs (AEDs), leading to a need for other treatment options, such as more aggressive use of AEDs, immunomodulatory therapy, the ketogenic diet (KD), vagus nerve stimulation (VNS), and/or surgery.

The KD is a high-fat low-carbohydrate adequate-protein diet that has been in use since 1921. Although its mechanism of action is not well defined, the KD has been shown to be effective in the treatment of refractory EE, and has been suggested as an early treatment option in very young children [5, 6, 7].


The effect of the KD on some encephalopathies, such as EMAS, IS or WS, DS, or LGS, is well established. However, its effect on others is only reported sporadically (i.e., epilepsy with focal migrating seizures in infancy, Febrile infection-related epilepsy syndrome, or myoclonic status in non-progressive encephalopathy, about which little is known).

In the treatment of epilepsy, the classic diet with a 1:4 or 1:3 ratio of fat to carbohydrates and proteins is used. Special formulas have been developed that facilitate the use of the diet in children with feeding difficulties due to severe neurological damage. Other diets are used today, such as the medium chain triglyceride (MCT) diet, the modified Atkins diet (MAD), and the low glycaemic index treatment (LGIT), have broadened the armamentarium for the treatment of children and adults with difficult-to-treat epilepsies.

Although the experience is sometimes anecdotal and consists mostly of case reports and series, the aim of this study was to present our own experience with the KD and an overview of the current literature on the diet in patients with EE.

**EARLY MYOCLONIC ENCEPHALOPATHY**

Early myoclonic encephalopathy (EME) is a syndrome with onset either in the neonatal period or the first months of life characterized by erratic, fragmentary, or massive myoclonus, partial seizures, and late tonic spasms. The EEG shows a typical burst-suppression pattern. Family and birth history are typically normal.

The infants show severe neurological impairment. Abnormal neurological behaviour may be present prior to onset of seizures. Head size is typically normal at onset, but microcephaly may develop over time. Severe developmental delay is seen with or without regression.

The etiology of EME may be metabolic or genetic/metabolic. In particular, nonketotic hyperglycaemia has been diagnosed in a large number of cases [8]. The prognosis for EME is poor, and there is no effective therapy.

In the literature, very few cases of EME treated with the KD have been published. Cusmai et al. [9] reported three cases affected by neonatal nonketotic hyperglycaemia and EME. In association with standard pharmacological therapy, the KD caused a dramatic reduction of seizures and improved quality of life. More recently, we studied two refractory cases with unknown etiology. The KD was introduced with 75-90% seizure-reduction, and a significant improvement of the EEG abnormalities. The burst-suppression pattern disappeared in both cases.

**INFANTILE SPASMS OR WEST SYNDROME**

Infantile spasms (IS), also known as West syndrome (WS), are the most common type of epileptic encephalopathy. Age at onset is between 3 and 7 months, but cases with onset before 3 months or after 12 months to 5 years are also found. The syndrome is characterized by spasms, arrest of psychomotor development, and a pattern of hypsarrhythmia on the EEG recording. The spasms are characterized by symmetric contractions of the trunk, with extension and elevation of the arms, and tonic extension of the legs lasting for less than 1 second to up to 5 seconds, and with clusters of 3-20 spasms typically occurring several times per day. Mild or severe developmental delay pre-exists in around 60% of the cases.

The etiology of IS is mostly structural and unknown in about 20%. Different mutations have been found in children with IS [10]. The prognosis for patients with IS is poor and related to the etiology.

Management options are vigabatrin or ACTH, which control the spasms in two-thirds of the patients. Final outcome may not be influenced by treatment. Resective neurosurgery can be indicated for selected cases with localized structural lesions.

The KD is relatively well studied in this group of patients. In 2001, Nordli et al. [13] published a retrospective review of 32 infants who had been treated with the KD. They found that infants with IS/myoclonic seizures did particularly well on the diet. The study is particularly relevant as it shows that it is possible to effectively use the diet in infants, against the previous beliefs that is was difficult to maintain the ketoses in this group of patients.

Ville et al. [14] reported a series of 42 consecutive patients with corticosteroid-resistant or -dependent epileptic encephalopathy treated with oral steroids combined with the KD. Four our of 23 patients with WS responded to the diet. The addition of the KD allowed withdrawing steroids in all responders.

Hirano et al. [15] reported six patients with IS who received the KD after other treatments had failed, including ACTH. Hypsarrhythmia disappeared 1 month after the introduction of KD in five of the patients. The frequency of IS fell by 80% in three patients, and disappeared in two of them; and no change was observed in one patient. Psychomotor
Some infants may have epileptic spasms and psychomotor development improved in five patients. Although tolerance to the diet was good, side effects, such as lethargy, anorexia, and unfavourable weight gain, were observed. Lee et al. [16] studied 69 patients with IS. Fourteen were put on the KD after they failed two or more AEDs, and seven of these patients became spasm-free.

Pires et al. [17] evaluated the effect of the KD in 17 infants with IS as a third-line treatment, after vigabatrin and steroids had failed. Six were seizure free after 1 month, and 11 were seizure free after 3 months on the diet. An additional AED (felbamate or topiramate) was given to all patients who did not become seizure free on the KD. The KD was well tolerated and felbamate led to an increase in the responder rate.

Numis et al. [18] studied the relationship of ketosis and growth to the efficacy of the KD in IS on 26 patients. At 1-3 months after diet initiation, 46% of patients had a greater than 90% reduction in IS. They found that the KD did not significantly alter the growth parameters of the patients.

Kang et al. [19] compared short-term (16 patients over 6-month period) and conventional long-term (24 patients over more than 2 years) KD treatment in patients with refractory IS who successfully completed the diet. The authors concluded that early response to the KD may indicate a successful early discontinuation of the KD and that the use of the KD for only 8 months in spasm-free children appears to be justified, with similar outcomes, recurrence rate, and less growth disturbance than with the longer-term, traditional use.

In a large study of 104 infants placed on the KD for IS after receiving a mean of 3.6 AEDs, Hong et al. [20] found that at 6 months, 64% of patients had over 50% spasm improvement, and 77% of patients improved after 1-2 years. 37% of patients became spasm-free for at least 6 months within a median 2.4 months of starting the KD. In addition to this, development improved in 62%, the EEG improved in 35%, and AEDs could be reduced in 29% of cases. Adverse effects were noted in 33%, of which 6% had diminished linear growth. Older age at onset of IS and fewer prior AEDs were more likely to be associated with more than 90% spasm improvement at 6 months.

Kossoff et al. [21] compared the results of the KD against ACTH for new-onset IS in a retrospective study, hypothesizing that the KD would have similar efficacy, but better tolerability than ACTH when used first-line. They found that the KD stopped spasms in 62% of cases, against the 90% registered on ACTH; however, those patients on the KD had fewer side effects and relapses than patients receiving ACTH. ACTH normalized the EEG more rapidly. In the five children where the KD was unsuccessful, four immediately became spasm-free with ACTH or topiramate. The authors concluded that the KD should be a first-line therapy for IS, with a 2-week time limit if unsuccessful.

We are currently evaluating 10 patients with WS treated with the KD. Three of them have an unknown etiology; one has become seizure free and two have had a 75-99% seizure reduction. Three patients with a structural etiology had a 50-75% seizure reduction. The remaining four patients did not respond to the diet. We believe the KD should be considered earlier in the treatment of WS, but not as the first option.

**Epileptic Spasms in Clusters Without Hypsarrhythmia**

Some infants may have epileptic spasms and psychomotor delay in the absence of documented hypsarrhythmia. These patients who lack hypsarrhythmia may be considered to have a variant of WS, rather than an electroclinically distinct epileptic syndrome. How to place this syndrome nosologically is beyond the scope of this review; however, it is worth noting that two of our patients have responded well to the diet.

The etiology of epileptic spasms in clusters without hypsarrhythmia is structural and a focal brain lesion should be considered (i.e., cortical dysplasia, tuberous sclerosis, or a tumor) [22]. Patients with a genetic or unknown etiology have also been described. The prognosis is poor as the epileptic spasms often do not respond to medical or surgical treatment [23].

Children with epileptic spasms in clusters without hypsarrhythmia may be candidates for ACTH therapy as the seizure pattern is identical to IS.

In our series of 48 patients with epileptic spasms without hypsarrhythmia [24], three patients were put on the KD. Seizure reduction was between 50% and 75% in one, between 25% and 50% in another, and the remaining patient did not respond to the treatment.

**Severe Myoclonic Epilepsy in Infancy or Dravet Syndrome**

Severe myoclonic epilepsy in infancy (SMEI) or Dravet syndrome (DS) is a rare disorder occurring in previously healthy infants. Age at onset is in the first year of life, with a peak at 5 months. The main clinical features are prolonged and repeated febrile and afebrile generalized or unilateral convulsive seizures, myoclonic jerks, and atypical absences most commonly occurring on arousal and during alert states. Seizures are often triggered by hot temperatures or fever.

The etiology is mostly genetic, related to mutations in sodium channel genes. One third of the children with DS show de novo mutations of the SCN1A gene, and additional familial genes probably contribute to the phenotype.

Molecular genetic testing is important, as the clinical features develop over time. Early diagnosis is key to prevent uncontrolled seizures leading to cognitive impairment.

DS is drug resistant. Some AEDs, such as carbamazepine, lamotrigine, and phenytoin, have been shown to worsen the seizures, while stiripentol in combination with valproate and clobazam may reduce them.

From our original series published in 2005 [25] and updated in 2011 [26], of 59 patients seen between 1990 and 2007, 24 were placed on the KD and were followed up for a minimum of 2 years. Sixteen (66.6%) of 24 patients remained on the diet. Two patients (12.5%) became seizure free; 10 children (62.5%) had a 75-99% decrease in seizures; and the remaining four (25%) had a 50-74% decrease in seizures. Furthermore, six patients have been off the diet for more than 2 years; one of them is seizure free, two have sporadic seizures, and three, who abandoned the diet after 3 years of adhering to it, relapsed. Twelve of 16 children who remained on the diet had a significant reduction in the number of seizures. Over the last years 20 new patients have been put on the diet with similar results. We consider that the KD is the most important treatment not only for the seizures but also for the febrile status epilepticus in patients with DS. In patients with an excellent response to the diet, neuropsychological performance improves significantly and thus, early treatment may avoid cognitive impairment.

Nabbout et al. [27] prospectively enrolled 15 DS patients over 3 years of age with a partial response to AEDs, includ-
absence, tonic-clonic and eventually tonic seizures, appear-

Doose syndrome is a generalized epilepsy syndrome associ-

Epilepsy with myoclonic and atonic seizures (EMAS) or

DOOSE SYNDROME

AND ATONIC SEIZURES OR

MIGRATING PARTIAL

SEIZURES IN INFANCY

Migrating partial seizures in infancy (MFSI) is an epileptic en-

cephalopathy with a seizure onset in the first 6 months of

life characterized by almost continuous migrating polymor-

phous focal seizures, associated with multifocal ictal EEG
discharges, progressive deterioration of psychomotor devel-

opment combined with frequent evolution of acquired micro-

cephaly, and a typical ictal electroencephalography pattern

consisting of seizures that arise independently and sequen-

tially from both hemispheres [30]. The etiology is probably
genetic with a heterogeneous basis [10].

The prognosis is poor as the seizures are resistant to

AEDs. However, some patients may respond favourably to

bromide, stiripentol associated with clonazepam, and leve-

tiracetam.

Results of KD treatment are variable in these patients [31].

At our centre, three patients who presented with MFSI re-

fractory to AEDs before 5 months of age were put on the

KD [32]. One of these patients became seizure-free and his

neurocognitive performance improved significantly. The oth-

er child had a seizure reduction of 75% to 99% with only

weekly seizures and moderate psychomotor improvement.

The remaining patient had a seizure reduction of less than

50%. Tolerability was good in all three patients.

Recently, we have been studying four new patients with

MFSI with an excellent response to the diet. Seizures de-

creased 75-99% in all subjects. Based on these positive

preliminary results, earlier initiation of the KD should be con-

sidered in the treatment of patients with MFSI.

EPILEPSY WITH MYOCOLNIC

AND ATONIC SEIZURES OR

DOOSE SYNDROME

Epilepsy with myoclonic and atonic seizures (EMAS) or

Doose syndrome is a generalized epilepsy syndrome associ-

ated with multiple seizure types, including myoclonic-astatic

absence, tonic-clonic and eventually tonic seizures, appear-

ing in a previously healthy child between 18 and 60 months

of age, with a peak around the age of 3 years. The course of

the disorder has variable severity [33]. Background EEG ac-

tivity can be normal at seizure onset, although characteristic

4-7 Hz monomorphic theta activity with diffuse distribution

but prominent in centro-parietal areas is often observed. In-

terctal abnormalities consist of bursts of 2-3 Hz generalized

polyspike-and-wave discharges. Sleep is accompanied by

an increase in generalized discharges [33].

Our series of 11 patients with EMAS placed on the KD

[34] showed the diet is a promising therapy with over half

of children showing a >50% reduction in seizures, and 18%

achieving seizure freedom. The patients that responded well

to the diet did not further mentally deteriorate. The youngest

child on the KD in our series of patients with EMAS was 4

years old. That is partly due to the fact that patients with

EMAS often respond well to AEDs and the KD is only tried

later in the treatment. We conclude that the KD should be

considered early in the course of the syndrome, and not as

a last resort.

Studies by Oguni et al., Sills et al., and Laux et al. also

suggest that the KD is the most effective therapy for patients

with EMAS [33, 35, 36].

MYOCLONIC STATUS EPILEPTICS IN

NONPROGRESSIVE ENCEPHALOPATHIES

OR DALLA BERNARDINA SYNDROME

Myoclonic status epilepticus in nonprogressive encephalopathies (MSENPE) is characterized by the recurrence of long-lasting status associated with absences and continu-

ous polymorphous myoclonias, mixed with other complex

abnormal movements in infants suffering from a nonprogres-

sive encephalopathy, independently of the etiology. Age at

first seizure ranges from 1 month to 4 years, with a mean age

of 16 months and a median age of 10 months.

This condition may be difficult to recognize clinically be-

cause of previous intellectual deficits and continuous abnor-

mal movements. However, it can be identified on polygraph-

ic recordings. [37]

The prognosis of MSENPE is poor. The children show

progressive deterioration resulting in severe neurocognitive

impairment. The myoclonic status resolves with age, but the

patients rarely achieve a relatively normal state.

The etiology can be diverse, but is mainly genetic and due
to a malformation of cortical development. Angelman syn-

drome is the most frequent underlying cause of MSENPE.

Awareness of this syndrome is important because, al-
though it occurs in children with severe neurological dam-

age, its diagnosis and treatment may improve the quality of

life of the patients and their families. There is no effective

treatment other than benzodiazepines, which transiently in-

terrupt the myoclonic status epileptics.

Our experience with three patients with MSENPE placed

on the KD was variable. One had a 75%-99% seizure-re-
duction; another one had a 50% seizure-reduction; and the

remaining case did not respond to the diet [37]. Three other

patients had a good response to KD with a more than 50% of

seizure-reduction (Dalla Bernardina, personal communi-

cation). In five of these six cases the etiology was genetic.

LENNOX-GASTAUT SYNDROME

Lennox-Gastaut syndrome (LGS) is a disorder characterized

by clusters of seizures and mental retardation, with an age at

onset from 1 to 7 years. Tonic seizures, atonic seizures, and

atypical absences are the characteristic seizures, in this or-
der of prevalence. Falls are common. Nonconvulsive status epilepticus of atypical absences, tonic and atonic seizures, and myoclonic jerks occur in half of the patients. Motor, cognitive, and behavioural abnormalities are found in around 60% of the patients prior to seizure onset. After that, nearly all have severe neurological and mental deficits.

Etiology is structural; in 70% of cases, there were severe brain disorders and malformations of cortical development. The remaining cases are unknown or genetic/metabolic cases.

The prognosis of LGS is poor; 5% of the patients die and 80% to 90% continue having seizures in adult life with severe neurological and mental deficits.

Complete seizure control is unlikely. Different AEDs and steroids are occasionally helpful. The KD has been successfully tried in different studies, although further studies are required to determine optimal timing to start the diet and which type of diet would be the best [38]. VNS is an option in patients with LGS [39]. Corpus callosotomy can be considered for intractable drop attacks.

In our series of 61 patients with LGS [40], 20 were placed on the diet. After 18 months, 15 patients (75%) remained on the diet; three patients (15%) were seizure free, three (15%) had a 75–99% decrease in seizures, two (10%) had a 50–74% decrease in seizures, and the remaining seven children (35%) had less than 50% decrease in seizures. Three seizure-free patients were taken off the diet after remaining seizure free. In the three patients who had a 75–99% decrease in seizures, AEDs were reduced. We found that the KD is an effective and well-tolerated treatment option for patients with LGS, not only for those with an unknown etiology, but also for those with structural LGS. The diet should be considered early in the course of this syndrome.

Lemmon et al. [41] retrospectively studied the records of 71 children, with LGS who were initiated on the KD between 1994 and 2010. They found that approximately one-half of children responded at 12 months.

Sharma et al. [42] used the MAD to treat 25 children with LGS. After 3 months, two patients were seizure-free and 10 had over 50% reduction in seizure frequency. At 6 months, three patients were seizure free, and eight had more than 50% reduction in seizure frequency. At 1 year, all nine children remaining on diet had more than 50% reduction in seizure frequency. The side effects of the diet were mild. The MAD was found to be effective and well tolerated in children with LGS.

**LANDAU-KLEFFNER SYNDROME (LKS) OR ACQUIRED EPILEPTIC APHASIA**

Landau-Kleffner syndrome (LKS), or acquired epileptic aphasia, is a rare disorder characterized by linguistic abnormalities (in 100% of cases) and seizures (in 75% of cases) in previously normal children. The age of onset ranges from 2-8 years, with a peak between 5 and 7 years. Onset as early as 18–22 months and as late as 13–14 years has also been reported. The most prominent feature of LKS is an acquired aphasia, typically, a verbal auditory agnosia. The loss of receptive language is followed by expressive aphasia, with a marked reduction in spontaneous speech. The aphasia demonstrates a subacute onset and a progressive course, with a fluctuating pattern of spontaneous improvements and exacerbations. Electroencephalographic findings during wakefulness may be bilateral centrotemporal, posterior temporal, and parieto-occipital spikes and waves. As soon as the patient falls asleep, continuous and diffuse slow spikes and waves appear, mainly at 1.5–2.5 Hz, persisting through all the slow-sleep stages. This pattern of continuous spike and wave during slow wave sleep (CSWS) or electrical status epilepticus in slow wave sleep (ESES) tends to be unilateral or clearly lateralized [43, 44].

Prognosis is variable. Cognitive and behavioural problems occur in more than 3/4 of patients. Complete language recovery is achieved in around 1/3 of patients, while the remaining patients continue to have language deficits of different degrees. The most frequently observed behavioural problems are attention deficit, impulsivity, distractibility, and hyperactivity.

By convention, the LKS is not related to brain organic lesions, and occurs in previously normal children who have already developed age-appropriate speech. However, there are reports of “clinically defined” LKS in patients with congenital or acquired brain lesions, and in children with demonstrated fairly substantial pre-existing anomalies of language development prior to their regression of language.

The most commonly used treatments are clobazam, ethosuximide, sulthiame. Steroids may also be considered. In refractory cases, gamma-globulins, the KD, and surgical treatment should be taken into consideration. Adequate and early treatment management may avoid language and cognitive deterioration.

Bergqvist [45] treated three patients with LKS refractory to traditional treatments who were successfully treated with the KD. All three patients had lasting improvement of their language, behaviour, and seizures for 26, 24, and 12 months, respectively.

**EPILEPSY WITH CONTINUOUS SPIKE-WAVES DURING SLOW WAVE SLEEP (CSWS)**

Epilepsy with continuous spike and wave during slow wave sleep (CSWS), also called electrical status epilepticus during slow-wave sleep (ESES), is an epileptic encephalopathy with an age onset between 2 months and 12 years, with a peak at 4 to 5 years. The etiology of CSWS may be genetic or probably genetic, structural, or unknown.

In the evolution of CSWS, three stages are distinguished. In the first stage, before CSWS, the child develops infrequent nocturnal focal motor seizures. In the second stage, with the onset of the CSWS, the frequency of the seizures increases, including typical and atypical absences, myoclonic absences, absence status epilepticus, atonic or clonic seizures, and generalized tonic-clonic seizures. Cognitive deterioration and behavioural disturbances occur. In the third stage, after months or years, the seizures remit and the child improves [3].

The prognosis is variable. The seizures remit in all cases and cognitive and behavioural disturbances improve. However, about half of the cases have severe residual deficits [46]. Seizures are not a major problem as their final prognosis is good. The most appropriate AEDs are valproate, lamotrigine, levetiracetam, and sulthiame. The CSWS may be refractory to classic AEDs, and steroid dependency may occur.

In a study by our group [47], of 65 children with CSWS, 12 (eight boys and four girls) were placed on the KD as add-on to the use of one to three AEDs. Eighteen months after initiating the KD, seven of the initial patients (58.3%) remained on the diet. One patient (8.3%) became seizure free; one child
(8.3%) had a 75%-99% decrease in seizures; two patients (16.6%) had a 50%-74% decrease in seizures, and the remaining three children (24.9%) had a less than 50% seizure reduction. Efficacy of the diet was not found to depend on etiology. We found that the KD is a well-tolerated treatment option for patients with CSWS, not only for structural cases but also for those with an unknown etiology.

Nikanorova [48] evaluated the effect of the KD on electroclinical characteristics and cognitive function in five children (four boys, one girl) aged between 8 and 13 years with CSWS refractory to conventional AEDs, including levetiracetam, and steroids. Electrographic evaluation after 24 months on the KD diet showed CSWS resolution in one patient, mild decrease of the spike-wave index in one, and lack of response in three patients. The KD did not influence the neuropsychological outcome, and intelligence quotient (IQ) scores remained low at the end of the follow-up period. Nevertheless, improvement in attention and behaviour was demonstrated in two patients. These results show that the KD did not appear to influence the neuropsychological outcome. However, the absence of a control group makes it impossible to draw any definite conclusions.

In the series of Ville et al. [14] of 42 consecutive patients where oral steroids were combined with the KD for corticosteroid-resistant or -dependent epileptic encephalopathy, 13 patients had CSWS; eight of them responded well to the diet. In this study, patients presenting with steroid-dependent CSWS seemed to be the best candidates.

FEBRILE INFECTION-RELATED EPILEPSY SYNDROME

Febrile infection-related epilepsy syndrome (FIRES) is a severe disorder that presents with intractable status epilepticus after a febrile illness in a previously healthy child. Onset is mostly between 3 and 15 years of age, although adults with FIRES have also been described. The syndrome is characterized by three phases: an initial phase with a simple febrile infection; an acute phase, which follows a few days later, with highly recurrent focal seizures that evolve rapidly into refractory status epilepticus, often with no more fever and generally without additional neurological features; and finally a chronic phase consisting of drug-resistant epilepsy and neuropsychological impairment [49].

The etiology of FIRES remains unknown. Immunological, genetic, infectious diseases studies have been unrevealing. Prognosis is poor as most children are left with mild to severe cognitive impairment and almost all continue to suffer from severe epilepsy.

In our series [50], three of 12 children with FIRES seen between 1997 and 2012 with a mean time of follow-up of 6.5 years (range, 1-15 years), two were put on the KD in the acute phase. One patient showed a good and sustained response, with a 50-75% seizure reduction; the remaining patients had a less than 50% seizure reduction. Two patients continue on a KD, and they have brief seizures every 2 and 4 months, respectively.

Sing et al. [51] reported two previously healthy school-aged children who presented with FIRES and were placed on the KD during the acute phase of their illness. Status epilepticus resolved in both. After some months on the KD and other AEDs, they were able to return to school, with some academic accommodations. The authors concluded that the KD may be the treatment of choice in FIRES and that early treatment may control seizures and improve cognitive outcome.

Nabbout et al. [52] studied nine patients with FIRES and refractory status epilepticus seen over 12 years. In seven patients the KD was efficacious. In one responder, early interruption of the diet was followed by relapse of intractable SE, and the patient died. The other six responders developed epilepsy within a few months.

In our last series of 21 patients, five patients were placed on the KD in the acute phase. Two had a 75%-99% seizure reduction; two had a 50%-74% reduction; and one did not respond to the diet.

CONCLUSION

The KD is well tolerated in paediatric patients, including infants, and should be considered early in the therapeutic scheme of EE in refractory cases, regardless of their etiology and age at onset.

Patients that responded well to the diet did not further mentally deteriorate and some even improved behavioural disturbances and cognitive performance.

It is very important to identify the groups of patients with EE in whom the KD works best. Other kinds of diet should also be considered in the treatment of patients with refractory EE.

Future controlled studies would be necessary to better define the efficacy and tolerability of the diet in patients with EE.

Acknowledgments
None.

Competing interests
The author has declared that there are no competing interests.

Cite this article as:
Caraballo: The use of the ketogenic diet in the treatment of epileptic encephalopathies. JICNA 2018 18:66
<table>
<thead>
<tr>
<th>Epilepsy syndrome</th>
<th>Clinical features</th>
<th>EEG features at presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Early infantile epileptic encephalopathy, or Ohtahara syndrome (OS)</strong></td>
<td>First 2 weeks of life</td>
<td><strong>Early infantile epileptic encephalopathy, or Ohtahara syndrome (OS)</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td>Tonic seizures</td>
<td><strong>Underlying etiology</strong></td>
</tr>
<tr>
<td><strong>Age of seizure onset</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Interictal</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Background</strong></td>
<td><strong>High voltage (150–350 uV) paroxysm</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>High voltage (150–350 uV) paroxysm</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Multifocal discharges, maximal in temporal and rolandic regions</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Multifocal epileptiform discharges with generalized electrodecrement</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Generalized, multifocal or focal discharges; photoparoxysmal response</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Focal/multifocal generalized discharges; marked sleep activation with increased interictal spatial distribution or bilateral synchrony; sleep spike wave index &gt;85%; CSWS-frontal predominant LKS-temporal predominant</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Relapsing-remitting course or age limiting by teenage years</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Mortality in childhood 10%, intellectual disability, or crouched gait without spasticity in adults</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Depends on etiology; other seizure types evolve by about 5 years</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Unknown; SCN1A, PLCB1, KCNT1 mutations; 2q24, 16p11.2 copy number variants</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>50% die within first year or profound disability</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>25% die by 2 years or evolves to WS and profound disability</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>First 2 weeks of life</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>First weeks of life</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>3–8 months</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>6 months</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>5–8 years</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>3–8 months</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Heterogenous (congenital cortical malformations, tuberous sclerosis, trisomy 21, trisomy 18, CDKL5, ARX, MECP2)</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Hemispheric background slowing</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Normal, generalized or focal slowing</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Mortality in childhood 10%, intellectual disability, or crouched gait without spasticity in adults</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Depends on etiology; other seizure types evolve by about 5 years</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Myoclonic seizures (erratic/fragmentary/gen-erated); focal seizures</strong></td>
</tr>
<tr>
<td><strong>Seizure types</strong></td>
<td><strong>Prognosis</strong></td>
<td><strong>Heterogenous (congenital cortical malformations, tuberous sclerosis, trisomy 21, trisomy 18, CDKL5, ARX, MECP2)</strong></td>
</tr>
</tbody>
</table>

Table 1: Summary of clinical characteristics and EEG features at presentation in early and childhood onset epileptic encephalopathy.
<table>
<thead>
<tr>
<th>Epilepsy syndrome</th>
<th>Clinical features</th>
<th>EEG features at presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age of seizure onset</td>
<td>Seizure types</td>
</tr>
<tr>
<td><strong>Lennox-Gastaut syndrome</strong> (LGS)</td>
<td>1–8 years</td>
<td>Multiple (tonic, atonic, absences, myoclonic, or focal)</td>
</tr>
<tr>
<td><strong>Myoclonic-atonic epilepsy</strong></td>
<td>7 months–6 years</td>
<td>Multiple (atonic, myoclonic, absences, or rarely tonic)</td>
</tr>
<tr>
<td><strong>Progressive myoclonic epilepsies</strong></td>
<td>Varies by etiology</td>
<td>Prominent myoclonic seizures</td>
</tr>
</tbody>
</table>

ESES: electrical status epilepticus in slow wave sleep; CSWS: Continuous spike and wave during slow wave sleep; LKS: Landau-Kleffner syndrome; WS: West syndrome
REFERENCES


14. Ville D, Chiron C, Laschet J, Dulac O. The ketogenic diet can be used successfully in combination with corticosteroids for epileptic encephalopathies. Epilepsy Behav. 2015 Jul;48:61-5.


31. Coppola G. The role of ketogenic diet. In Seizures and syndromes of onset in the two first years of life. Edited by Moshé S, Cross JH, Bellescize de J, Vries de L, Nor-


